DAMM                                                                                                                                                                           KANTAR: Binomio farmaco-erogatore nell'aerosolterapia della patologie flogistiche delle vie respiratorie                          MARINIELLO: La terapia inalatoria

1) A. Fiocchi (Milano) - Fattori che influenzano la deposizione dell'aerosol nei polmoni  (Consensus Conference “Current best practice for neluliser treatment” – Verona, 12-13 luglio 2002)

2) A. Kantar   (Bergamo) - STEROIDI DA NEBULIZZARE(Consensus Conference “Current best practice for neluliser treatment” – Verona, 12-13 luglio 2002)

3) Pneumologia pediatrica, volume 3, numero 12, dicembre 2003.

1. Corsico R. Tecniche di aerosol terapia. In:  “Trattato Italiano di Allergologia”.Volume 2. Pavia: Selecta Medica ed. 2002; 1115-1125.

2. Muers MF. Overview of nebuliser treatment. Thorax 1997; 52: S25-S30.

3. Kondili E, Georgopoulos D. Aerosol medications.  Respir Care Clin N Am 2002; 8: 309-334.

4. O’Callaghan C, Barry PW. The science of nebulizer drug delivery. Thorax 1997; 52: S31-S44.

5. Task Group on Lung Dynamics. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Physics 1966; 12: 173-208.

6. Stalhhofen W, Gebbert J, Heyder J. Experimental determination of the regional deposition of the aerosol particles in the human respiratory tract. Am Ind Hyg Assoc J 1980; 41: 385-399.

7. Melandri C,Tarroni G, Prodi V, et al. Deposition of charged particles in the human airways. J Aerosol Sci 1985; 29: 229-240.

8. Prodi V, Mularoni A. Electrostatic lung deposition experiments with human and animals. Ann Occup Hyg 1985; 29: 229-240.

9. Goodman & Gilman A. Assorbimento polmonare. In: “Le basi farmacologiche della terapia”. Milano: McGraw-Hill ed. 1997; 8.

10. Pedersen S. Inhalers and nebulizers: which to choose and why. Respiratory Medicine 1996; 90: 69-77.

11. Goodman-Gilman A. Farmaci utilizzati nella terapia dell’asma bronchiale. McGraw-Hill ed. 652-655.

12. Aerosol Consensus Statement. Consensus conference on aerosol delivery. Chest 1991; 100: 1106-1109

13. Shultz RK. Drug delivery characteristics of metered-dose inhalers. J Allergy Clin Immunol 1995; 96: 284-287.

14. Zanudin BMZ, Biddiscombe M,Tolfree SEJ, et al. Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurized metered dose inhaler, as a dry powder, and as a nebulised solution. Thorax 1990; 45: 469-473.

15. Newman SP, Clark AR,Talence R, Clarke SW. Pressurized aerosol deposition in the human lung with and without an open spacer device. Thorax 1989; 44: 706-710.

16.Tal A, Golan H, Grauer N, et al. Deposition pattern of radiolabelled salbutamol inhaled from a metered dose unhalers by means of a spacer with mask in young children with airway obstruction. J Pediatr 1996; 128: 479-484.

17. Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulized or pressurized metered dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135: 28-33.

18. Melchor R, Biddiscombe MF, Mak WH, et al. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993; 48: 506-511.

19. Di Berardino L. Strumenti per la nebulizzazione (nasale e bronchiale). In: “Ausili strumentali per la prevenzione e la terapia delle malattie allergiche”. Pisa: Pacini Editore 2000; 68.

20. Hardy JG, Newman SP, Knoch M. Lung deposition from four nebulizers. Respir Med 1993; 87: 461-465.